Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China
First glucokinase-activator (GKA) approval outside mainland China Approval supports a differentiated approach to T ype 2 diabetes (T2D) management Hong Kong will serve as H ua Medicine's launchpad for international market expansion SHANGHAI and HONG...